

## Innspill i forbindelse med EFSA's Offentlige høring av mais MON 87427 x MON 87460 x MON 89034 x MIR162 x NK603 (EFSA-GMO-NL-2016-134)

### **Food and feed safety assessment**

1. The applicant has not provided new experimental data that exclude possible combined effects of the newly expressed proteins in the stacked event. Different modes of action do not necessarily exclude interaction.
2. Most immunologic adjuvant experiments on Cry –proteins have been performed on Cry1Ac, and some of these studies have indicated adjuvant properties (VKM, 2012). To our knowledge, Cry1A.105 and Cry2Ab2 proteins have not been studied experimentally for potential adjuvant properties. Although these proteins do not show sequence resemblance to known adjuvants like cholera toxin or E. coli heat-labile enterotoxin, the VKM GMO Panel highlights the need for further clarification on the potential role of these proteins as adjuvants as part of the risk assessment. This may be of particular importance for high-protein fractions, e.g. maize gluten meal, produced under low temperatures, since levels of the transgenic proteins are up-concentrated in these fractions.
3. The Norwegian scientific committee would have preferred that the applicant performs a nutritional feeding study with animals, e.g. broilers, that could be fed a high inclusion level of unprocessed maize in their diets.
4. The VKM GMO panel is of the opinion that data on residue levels of the intended herbicide glyphosate should have been provided by the applicant.